Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
J Cell Physiol ; 229(7): 903-15, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24501087

ABSTRACT

The extracellular signal-regulated kinase (ERK)1/2 mitogen-activated protein (MAP) kinase pathway has been involved in the positive and negative regulation of cell proliferation. Upon mitogen stimulation, ERK1/ERK2 activation is necessary for G1- to S-phase progression whereas when hyperactived, this pathway could elicit cell cycle arrest. The mechanisms involved are not fully elucidated but a kinase-independent function of ERK1/2 has been evidenced in the MAPK-induced growth arrest. Here, we show that p70S6K, a central regulator of protein biosynthesis, is essential for the cell cycle arrest induced by overactivation of ERK1/2. Indeed, whereas MEK1 silencing inhibits cell cycle progression, we demonstrate that active mutant form of MEK1 or MEK2 triggers a G1 phase arrest by stimulating an activation of p70S6K by ERK1/2 kinases. Silencing of ERK1/2 activity by shRNA efficiently suppresses p70S6K phosphorylation on Thr421/Ser424 and S6 phosphorylation on Ser240/244 as well as p21 expression, but these effects can be partially reversed by the expression of kinase-dead mutant form of ERK1 or ERK2. In addition, we demonstrate that the kinase p70S6K modulates neither the p21 gene transcription nor the stability of the protein but enhances the translation of the p21 mRNA. In conclusion, our data emphasizes the importance of the translational regulation of p21 by the MEK1/2-ERK1/2-p70S6K pathway to negatively control the cell cycle progression.


Subject(s)
MAP Kinase Kinase 1/genetics , MAP Kinase Kinase 2/genetics , MAP Kinase Signaling System/genetics , Ribosomal Protein S6 Kinases, 70-kDa/genetics , Cell Cycle Checkpoints/genetics , Cell Proliferation , Cyclin-Dependent Kinase Inhibitor p21/biosynthesis , Cyclin-Dependent Kinase Inhibitor p21/genetics , G1 Phase Cell Cycle Checkpoints/genetics , Hep G2 Cells , Humans , MAP Kinase Kinase 1/biosynthesis , MAP Kinase Kinase 2/biosynthesis , Phosphorylation , Protein Biosynthesis , RNA, Small Interfering , Ribosomal Protein S6 Kinases, 70-kDa/biosynthesis , Signal Transduction
2.
Anticancer Res ; 31(2): 549-53, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21378337

ABSTRACT

AIM: Expression of mitogen-activated protein kinase (MAPK) signaling and its role in cell proliferation of the bone malignancies, osteosarcoma (OS) and malignant fibrous histiocytoma (MFH) were investigated. MATERIALS AND METHODS: Gene expression and protein levels of RAF1 and MEK1/2 in 6 human sarcoma cell lines and 7 surgically obtained OS specimens were assessed by RT-PCR and immunohistochemistry, respectively. MEK inhibitor, U0126 [1,4-diamino-2,3-dicyano-1,4-bis (2-aminophynyltio) butadiene], was used for cell proliferation assays. RESULTS: RAF1 and MEK 1/2 mRNA was detected in all cell lines and OS specimens. RAF1, MEK 1/2 and p-MEK protein was also expressed in the cells, as was MEK1/2 in OS specimens. Treatment with U0126 resulted in dose- and time-dependent inhibition of cell proliferation and suppression of p-ERK expression, opposite to promotion of p-MEK. CONCLUSION: U0126 blocks MAPK signaling and decreases cell proliferation in OS and MFH. Thus, selective MAPK inhibitors might be therapeutically advantageous in the treatment of bone and soft tissue sarcomas.


Subject(s)
Bone Neoplasms/enzymology , Histiocytoma, Malignant Fibrous/enzymology , MAP Kinase Signaling System/physiology , Osteosarcoma/enzymology , Blotting, Western , Bone Neoplasms/drug therapy , Bone Neoplasms/pathology , Butadienes/pharmacology , Cell Growth Processes/drug effects , Cell Growth Processes/physiology , Cell Line, Tumor , Dose-Response Relationship, Drug , Histiocytoma, Malignant Fibrous/drug therapy , Histiocytoma, Malignant Fibrous/pathology , Humans , Immunohistochemistry , MAP Kinase Kinase 1/antagonists & inhibitors , MAP Kinase Kinase 1/biosynthesis , MAP Kinase Kinase 1/genetics , MAP Kinase Kinase 2/antagonists & inhibitors , MAP Kinase Kinase 2/biosynthesis , MAP Kinase Kinase 2/genetics , MAP Kinase Signaling System/drug effects , Nitriles/pharmacology , Osteosarcoma/drug therapy , Osteosarcoma/pathology , Protein Kinase Inhibitors/pharmacology , Proto-Oncogene Proteins c-raf/antagonists & inhibitors , Proto-Oncogene Proteins c-raf/biosynthesis , Proto-Oncogene Proteins c-raf/genetics , RNA, Messenger/biosynthesis , RNA, Messenger/genetics
3.
Biochem Biophys Res Commun ; 402(3): 554-9, 2010 Nov 19.
Article in English | MEDLINE | ID: mdl-20974109

ABSTRACT

Oligonol is a lychee fruit-derived low-molecular form of polyphenol. In this study, the effect of Oligonol on the mitogen activated-protein kinase (MAPK) signaling pathway in primary adipocytes was investigated to examine the mechanism underlying the enhanced levels of phosphorylated extracellular-signaling regulatory kinase1/2 (ERK1/2) that accompany an in vitro increase in lipolysis. Oligonol significantly elevated the levels of activated Ras and the phosphorylation of Raf-1 and MAPK/ERK kinase1/2 (MEK1/2) with no increase in pan-Raf-1 and -MEK1/2 proteins. The increase in phosphorylation of Raf-1 and MEK1/2 with Oligonol was inhibited completely by pretreatment with GW5074, a selective Raf-1 inhibitor, or PD98059, a selective MEK1/2 inhibitor. IL-6 also activated the MAPK signaling pathway in adipocytes through the association with its receptor. IL-6-induced phosphorylation of Raf-1 and MEK1/2 was significantly inhibited by pretreatment with the IL-6 receptor antibody. Under such a condition, however, the levels of phosphorylated Raf-1 and MEK1/2 with Oligonol still remained significantly higher, and there was a significant decrease in secretion of IL-6 from adipocytes, compared with untreated control cells. These results suggest that Oligonol activates the Ras/Raf-1/MEK1/2 signaling pathway, independent of the IL-6 signaling pathway, leading to activation of ERK1/2 proteins in primary adipocytes.


Subject(s)
Adipocytes/drug effects , Anti-Obesity Agents/pharmacology , Catechin/analogs & derivatives , Phenols/pharmacology , Adipocytes/enzymology , Animals , Catechin/pharmacology , Flavonoids/pharmacology , Fruit/chemistry , Interleukin-6/metabolism , Interleukin-6/pharmacology , Litchi/chemistry , MAP Kinase Kinase 1/biosynthesis , MAP Kinase Kinase 2/biosynthesis , Male , Obesity/enzymology , Polyphenols , Proto-Oncogene Proteins c-raf/biosynthesis , Rats , Rats, Wistar , ras Proteins/biosynthesis
4.
Biochem Biophys Res Commun ; 385(4): 523-7, 2009 Aug 07.
Article in English | MEDLINE | ID: mdl-19465001

ABSTRACT

Biological roles of ERK and MEK in signal transduction have been controversial. The aim of the current study was to determine the role of ERK1/2 in signaling through the ERK-MAPK cascade by using RNAi methodology. Transient transfection of erk1 or erk2 siRNA decreased the respective protein level to 3-8% in human lung fibroblasts. Interestingly, individual ERK isoform silencing resulted in a 2-fold reciprocal increase in phosphorylation of the alternate ERK isoform, with no change in respective total protein expression. Moreover, MEK was hyperphosphorylated as a result of combined ERK1 and ERK2 silencing, but was unaffected in individual ERK1 or ERK2 silenced cells. This hyperactivation of MEK was not due to activation of Raf family members, but rather was associated with PP2A downregulation. These data highlight the existence of a feedback loop in normal cells whereby ERK silencing is associated with decreased PP2A activity and consequent MEK activation.


Subject(s)
MAP Kinase Kinase 1/biosynthesis , MAP Kinase Kinase 2/biosynthesis , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3/metabolism , Protein Phosphatase 2/metabolism , Cells, Cultured , Enzyme Activation , Feedback, Physiological , Gene Silencing , Humans , Mitogen-Activated Protein Kinase 1/genetics , Mitogen-Activated Protein Kinase 3/genetics , Phosphorylation , RNA, Small Interfering/genetics , Transfection , raf Kinases/metabolism
5.
Skin Pharmacol Physiol ; 19(5): 259-65, 2006.
Article in English | MEDLINE | ID: mdl-16778458

ABSTRACT

Procyanidin oligomers are polyphenol compounds we have identified in apples and barley which have hair growth stimulant effects, and which are able to promote hair epithelial cell growth and induce anagen induction of the hair cycle in the in vivo murine model. For the purpose of examining the hair-growing mechanisms of procyanidin oligomers, we examined their relationship to the TGF-beta signal pathway, known to be a regulator of catagen induction, and the mitogen-activated protein kinase cascade linked to cell proliferation. Addition of TGF-beta(1) or TGF-beta(2) to hair epithelial cell cultures dose-dependently decreased cell growth and induced apoptosis; however, addition of procyanidin B-2 to the culture neutralized the growth-inhibiting effects of both TGF-beta(1) and TGF-beta(2) and protected the cells from apoptosis. The same effects were observed with procyanidin B-3. We confirmed that procyanidin B-2 upregulates the expression of MEK-1/2 in cultured murine hair epithelial cells. We speculate that the hair-growing activity of procyanidin oligomers is at least linked to their growth-promoting effects on hair epithelial cells that follow MEK activation and their protective action on TGF-beta(1)- or TGF-beta(2)-induced apoptosis that is assumed to trigger catagen induction in the hair cycle.


Subject(s)
Apoptosis/drug effects , Biflavonoids/pharmacology , Catechin/pharmacology , Hair/drug effects , Proanthocyanidins/pharmacology , Transforming Growth Factor beta/pharmacology , Animals , Cells, Cultured , Dose-Response Relationship, Drug , Epithelial Cells/drug effects , Hair/cytology , MAP Kinase Kinase 1/biosynthesis , MAP Kinase Kinase 2/biosynthesis , Mice , Mice, Inbred C3H , Transforming Growth Factor beta1 , Transforming Growth Factor beta2
6.
J Biol Chem ; 280(52): 42644-54, 2005 Dec 30.
Article in English | MEDLINE | ID: mdl-16239230

ABSTRACT

Protein serine/threonine phosphatase 2A (PP2A) regulates a wide variety of cellular signal transduction pathways. The predominant form of PP2A in cells is a heterotrimeric holoenzyme consisting of a scaffolding (A) subunit, a regulatory (B) subunit, and a catalytic (C) subunit. Although PP2A is known to regulate Raf1-MEK1/2-ERK1/2 signaling at multiple steps in this pathway, the specific PP2A holoenzymes involved remain unclear. To address this question, we established tetracycline-inducible human embryonic kidney 293 cell lines for overexpression of FLAG-tagged Balpha/delta regulatory subunits by approximately 3-fold or knock-down of Balpha by greater than 70% compared with endogenous levels. The expression of functional epitope-tagged B subunits was confirmed by the detection of A and C subunits as well as phosphatase activity in FLAG immune complexes from extracts of cells overexpressing the FLAG-Balpha/delta subunit. Western analysis of the cell extracts using phosphospecific antibodies for MEK1/2 and ERK1/2 demonstrated that activation of these kinases in response to epidermal growth factor was markedly diminished in Balpha knock-down cells but elevated in Balpha- and Bdelta-overexpressing cells as compared with control cells. In parallel with the activation of MEK1/2 and ERK1/2, the inhibitory phosphorylation site of Raf1 (Ser-259) was dephosphorylated in cells overexpressing Balpha or Bdelta. Pharmacological inhibitor studies as well as reporter assays for ERK-dependent activation of the transcription factor Elk1 revealed that the PP2A holoenzymes ABalphaC and ABdeltaC act downstream of Ras and upstream of MEK1 to promote activation of this MAPK signaling cascade. Furthermore both PP2A holoenzymes were found to associate with Raf1 and catalyze dephosphorylation of inhibitory phospho-Ser-259. Together these findings indicate that PP2A ABalphaC and ABdeltaC holoenzymes function as positive regulators of Raf1-MEK1/2-ERK1/2 signaling by targeting Raf1.


Subject(s)
Gene Expression Regulation, Enzymologic , MAP Kinase Kinase 1/biosynthesis , MAP Kinase Kinase 2/biosynthesis , Mitogen-Activated Protein Kinase 1/biosynthesis , Mitogen-Activated Protein Kinase 3/biosynthesis , Phosphoprotein Phosphatases/chemistry , Proto-Oncogene Proteins c-raf/biosynthesis , Blotting, Western , Catalytic Domain , Cell Line , Dimerization , Enzyme Activation , Enzyme Inhibitors/pharmacology , Epitopes/chemistry , Humans , Immunoblotting , Immunoprecipitation , Luciferases/metabolism , MAP Kinase Signaling System , Phosphoprotein Phosphatases/metabolism , Phosphorylation , Plasmids/metabolism , Protein Phosphatase 2 , RNA Interference , Reverse Transcriptase Polymerase Chain Reaction , Serine/chemistry , Signal Transduction , Tetracycline/pharmacology , Transfection
7.
Int J Oncol ; 25(5): 1303-9, 2004 Nov.
Article in English | MEDLINE | ID: mdl-15492819

ABSTRACT

In our previous investigations, mitogen-activated protein kinase kinase 2 (MEK2)/extracellular signal-regulated kinase 2 (ERK2) signaling pathway was found to be correlated with the cell dissociation induced by dissociation factor (DF) in pancreatic cancer cells. In this study, the expressions of epidermal growth factor receptor (EGFR), phosphorylated EGFR (p-EGFR), and its downstream kinases MEK1/2 and ERK1/2, were analyzed to clarify the regulatory mechanism of cell dissociation in pancreatic cancer cells. Two hamster (PC-1.0 and PC-1) and two human (AsPC-1 and Capan-2) pancreatic cancer cell lines were used. Immunocytochemical study was performed using anti-EGFR, p-EGFR, phosphorylated MEK1/2 (p-MEK1/2), and phosphorylated ERK1/2 (p-ERK1/2) antibodies. DF-treatment markedly induced the expressions of EGFR, p-EGFR, p-MEK1/2, p-ERK1/2, as well as the dissociation of cell colonies in PC-1 and Capan-2 cells. In contrast, AG1478 (an EGFR inhibitor) treatment significantly induced the cell aggregation in PC-1.0 and AsPC-1 cells which usually grew as single cells, but strongly suppressed the expressions of EGFR, p-EGFR, p-MEK1/2, and p-ERK1/2. These observations demonstrate that activation of EGFR is closely involved in cell dissociation in pancreatic cancer through activating MEK/ERK signaling pathway.


Subject(s)
Adenocarcinoma/genetics , Adenocarcinoma/physiopathology , Cell Movement/genetics , Cell Movement/physiology , ErbB Receptors/biosynthesis , Pancreatic Neoplasms/genetics , Pancreatic Neoplasms/physiopathology , Animals , Cricetinae , ErbB Receptors/genetics , ErbB Receptors/metabolism , Immunohistochemistry , MAP Kinase Kinase 1/biosynthesis , MAP Kinase Kinase 2/biosynthesis , Mesocricetus , Mitogen-Activated Protein Kinase 1/biosynthesis , Mitogen-Activated Protein Kinase 3/biosynthesis , Neoplasm Invasiveness/genetics , Neoplasm Invasiveness/physiopathology , Neoplasm Metastasis/genetics , Neoplasm Metastasis/physiopathology , Phosphorylation , Signal Transduction , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...